contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


mod-ledelsen-i-rovsing-expres2ion-biotechnologies-dfds-og-alk-og-stil-sporgsmal-til-dagens-investorpraesentationer

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Philip Coombes

Rovsing is a technology company. The company specializes in technical development of systems, products and software solutions for the satellite and space industry. Examples of solutions that the company develops are check-out and validation systems. In addition, related engineering services are offered. Rovsing was founded in 1992 and is headquartered in Glostrup.

Rovsing

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

DFDS is a Danish based ferry and logistics provider in Europe and Turkey, listed on the Nasdaq OMX Copenhagen Stock Exchange, with a history dating back to 1866. The company’s ferry division operates ferry routes around Europe transporting both freight and around 5 million passengers per year. Its ferry division is its primary revenue driver, and it has a presence in the North Sea, Baltic Sea, Mediterranean Sea, and the English Channel.

DFDS also offers a wide range of freight services, rooted in the regions served by its ferry routes, they range from door-door transports of full loads, to complex solutions for major industries. Its major customers include forwarders and hauliers as well as manufacturers of heavy industrial goods.

DFDS

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.


ALK-Abelló

Mød ledelsen i Rovsing, ExpreS2ion Biotechnologies, DFDS, og ALK, og stil spørgsmål til dagens investorpræsentationer

Her til formiddag kl. 10:00 vil Rovsing CEO Hjalti Pall Thorvardarson pr&#xe6;sentere resultaterne Q1 2025/26 og svare p&#xe5; sp&#xf8;rgsm&#xe5;l fra publikum. Tilmeld dig og stil dine sp&#xf8;rgsm&#xe5;l allerede nu: <a href="https://www.inderes.dk/videos/rovsing-praesentation-af-resultater-for-forste-kvartal-202526">https://www.inderes.dk/videos/rovsing-praesentation-af-resultater-for-forste-kvartal-202526</a>
I dag kl. 11:00 vil ExpreS2ion Biotechnologies CEO Bent U. Frandsen og CFO Keith Alexander pr&#xe6;sentere resultaterne for Q3 2025 og svare p&#xe5; sp&#xf8;rgsm&#xe5;l fra publikum. Tilmeld dig og stil dine sp&#xf8;rgsm&#xe5;l allerede nu: <a href="https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q3-2025-earnings-release">https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q3-2025-earnings-release</a>
I dag kl. 11:30 vil DFDS CEO Torben Carlsen pr&#xe6;sentere resultaterne for Q3 2025 og svare p&#xe5; sp&#xf8;rgsm&#xe5;l fra publikum. Tilmeld dig og stil dine sp&#xf8;rgsm&#xe5;l allerede&#xa0;nu: <a href="https://www.inderes.dk/videos/dfds-praesentation-af-regnskabet-for-3-kvartal-2025">https://www.inderes.dk/videos/dfds-praesentation-af-regnskabet-for-3-kvartal-2025</a>
Her til eftermiddag kl. 15:00 vil ALK EVP &amp; CFO Claus Steensen S&#xf8;lje og VP &amp; Head of IR Per Plotnikof pr&#xe6;sentere resultaterne for Q3 2025 og svare p&#xe5; sp&#xf8;rgsm&#xe5;l fra publikum. Tilmeld dig og stil dine sp&#xf8;rgsm&#xe5;l allerede nu: <a href="https://www.inderes.dk/videos/alk-praesentation-af-q3-2025">https://www.inderes.dk/videos/alk-praesentation-af-q3-2025</a>
Disclaimer: HC Andersen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR abonnementsaftale. /Philip Coombes d. 13/11-2025 kl. 08:45.

HC Andersen Capital

<ul><li>Rovsing CEO Hjalti Pall Thorvardarson præsenterer Q1 2025/26 resultater kl. 10:00 og besvarer spørgsmål fra publikum.</li><li>ExpreS2ion Biotechnologies CEO Bent U. Frandsen og CFO Keith Alexander præsenterer Q3 2025 resultater kl. 11:00 med mulighed for publikumsspørgsmål.</li><li>DFDS CEO Torben Carlsen præsenterer Q3 2025 resultater kl. 11:30 og vil besvare spørgsmål fra deltagerne.</li><li>ALK EVP & CFO Claus Steensen Sølje og VP & Head of IR Per Plotnikof præsenterer Q3 2025 resultater kl. 15:00 med efterfølgende Q&A session.</li></ul>Dette indhold er genereret af AI. Du kan give feedback om det på Inderes <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/last">forum</a>.

Mød ledelsen i Rovsing, ExpreS2ion Biotechnologies, DFDS, og ALK, og stil spørgsmål til dagens investorpræsentationer

Summary

Stay up to date